Clinical Trial Search

Primary: Percentage of Participants With a Clinically Relevant Decrease in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) Score…

Primary: Change in ESSDAI Total Score — -3.77; -5.54; 11.52; 13.12 score on a scale

Primary: Blood Cell Gene Expression — -0.0291486; 0.1330903; 0.2509076; 0.06726222 log 2 fold change — p=0.0000496

Primary: The Xerostomia Inventory — 40.2; 39.3 units on a scale — p=0.05

Primary: Change From Baseline in European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) Score at Day 99 — -2.3; -3.8 Scores on a scale — p=0.262

Primary: Number of Participants With Primary Sjögren's Syndrome With Adverse Events and Death up to Day 85 — 20; 8; 1; 0 count of participants

Primary: Number of Participants With Serious Adverse Events (SAE) and Non-serious AEs (Non-SAE) — 0; 3; 2; 4 Participants

Primary: Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) — -3.2; -3.7 Score on a Scale — p=0.4421

Primary: Percentage of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline — 42.9; 43.2; 35.1; 26.5 percentage of participants…

Primary: Mean Change in Cornea Staining — -1.78 units on a scale

Primary: Schirmer Testing — 10.2; 0.8; 13.5 mm.

Primary: Change From Baseline to Week 12 in ESSDAI Score — -5.60; -5.29 score on a scale

Primary: Change From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) — 12.0; 11.8; 10.6; 11.0 units on a scale — p=0.397

Primary: Cohort 1: Change in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) Score From Baseline at 24 Weeks as Compared to Placebo — -4.0; -7.0; -5.4; -6.9 Unit on a…

Primary: Overall Improvement Rate in Dry Mouth Symptoms — 26.0; 20.0; 44.0; 27.1 percentage of participants

Primary: Change in The European League Against Rheumatism (EULAR) Sjogren's Syndrome Patient Reported Index (ESSPRI) Score From Baseline to Week 24 — -0.125 score on a scale

Primary: Number of Participants Diagnosed With Rheumatoid Arthritis Also Found to Have Dry Eye Disease — 275 participants

Primary: Number of Participants With TEAEs, TESAEs and TEAESIs — 15; 6; 0; 2 Participants

Primary: Population 1: Change From Baseline in ESSDAI at Day 169 — -4.1; -6.3 Score on scale

Primary: Proportion of Participants With a 1 Point or Greater Change on the Salivary Gland Ultrasound (SGUS) Score for Parotid and Submandibular Glands — 0; 0 Participants

Primary: Change From Baseline to Week 12 in Total Corneal Fluorescein Staining — -2.55; -0.37 units on a scale

Primary: Change in Levels of Biomarkers After Dosing With Maxidex — -1.244; -0.29; -0.033; -0.33 ddCt (Delta-Delta-Ct)

Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24

Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm

Primary: Standardized Uptake Value (SUV) for 18F-FDG for pSS Participants in Selected Body Areas — 2.9067; 5.0683; 4.0225; 1.4558 Grams per milliliter

Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted

Primary: Change From Baseline in Oral Aperture Measurement — 32.98; 32.92; 33.40; 34.37 milimeters — p=0.564

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 0; 0; 127; 43 Participants

Primary: Least Squares Mean Change From Baseline in ESSDAI Score at Week 24 — -6.39; -5.64; -6.93; -8.30 Scores on a scale — p=0.5161

Primary: Change in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) — 11.1; 14.5; 11.5; 12.5 units on a scale — p=0.678